Of note is that these editing technologies may be applied to both tumor suppressors that are inactivated mostly by mutations and not deletions, such as PTEN, TP53, RB1 and NF1, and to oncogenes, such as PIK3CA [45]. The gene discussed is PTEN; the disease is neoplasm.